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Abstract: Psychopharmacological research, if properly designed, may offer insight into both timing and
area of effect, increasing our understanding of the brain’s neurotransmitter systems. For that purpose,
the acute influence of the selective serotonin reuptake inhibitor citalopram (30 mg) and the acetylcholin-
esterase inhibitor galantamine (8 mg) was repeatedly measured in 12 healthy young volunteers with rest-
ing state functional magnetic resonance imaging (RS-fMRI). Eighteen RS-fMRI scans were acquired per
subject during this randomized, double blind, placebo-controlled, crossover study. Within-group compar-
isons of voxelwise functional connectivity with 10 functional networks were examined (P< 0.05, FWE-
corrected) using a non-parametric multivariate approach with cerebrospinal fluid, white matter, heart
rate, and baseline measurements as covariates. Although both compounds did not change cognitive per-
formance on several tests, significant effects were found on connectivity with multiple resting state net-
works. Serotonergic stimulation primarily reduced connectivity with the sensorimotor network and
structures that are related to self-referential mechanisms, whereas galantamine affected networks and
regions that are more involved in learning, memory, and visual perception and processing. These results
are consistent with the serotonergic and cholinergic trajectories and their functional relevance. In
addition, this study demonstrates the power of using repeated measures after drug administration,
which offers the chance to explore both combined and time specific effects. Hum Brain Mapp 00:000–000,
2016. VC 2016 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.
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INTRODUCTION
Drugs acting on serotonin (5-hydroxytryptamine; 5-HT)
and acetylcholine (ACh) are known for their regulating
influence on behavior and cognition. Selective serotonin
reuptake inhibitors (SSRIs) are accepted for their mood
altering properties and usually prescribed to treat dep-
ression and anxiety disorders [Carr and Lucki, 2011;
Jacobs and Azmitia, 1992]. Acetylcholinesterase inhibitors
(AChEIs) are found to be beneficial in neurodegenerative
disorders [Alzheimer’s disease (AD), dementia with Lewy
bodies and Parkinson’s disease] due to their effect on
attention, learning, and memory [Perry et al., 1999; Soreq
and Seidman, 2001].
The brain’s serotonergic axonal pathways originate in
the midbrain’s medial and dorsal raphe nuclei. In the cen-
tral nervous system (CNS), a particularly high density of
5-HT receptors is observed in the cerebral cortex, limbic
structures, basal ganglia and brain stem regions [Daubert
and Condron, 2010; Tork, 1990]. For ACh, the major source
is the basal forebrain, with fibers diffusing to the cortex,
amygdala, and hippocampus [Benarroch, 2010]. The find-
ing that specific neurotransmitters like 5-HT and ACh also
act as neuromodulators, has led to the formation of dis-
tributed computational network models [Baxter et al.,
1999; Doya, 2002; Marder and Thirumalai, 2002]. Conse-
quently, studies of cholinergic or serotonergic drug effects
also need to consider their extensive modulatory effects
[Bargmann, 2012]. This is possible with resting state func-
tional magnetic resonance imaging (RS-fMRI) in the con-
text of pharmacological stimulation [Fox and Raichle, 2007;
Khalili-Mahani et al., 2014].
Evidence is growing on the sensitivity of resting state
networks, consisting of regions with coherent blood-
oxygen-level-dependent fluctuations, to pharmacological
challenges [Cole et al., 2013; Khalili-Mahani et al., 2012,
2015; Klumpers et al., 2012; Niesters et al., 2012]. These
networks have consistently been found in healthy and
clinical conditions, and are related to specific functions of
the brain (i.e., motor, auditory, visual, emotional, and
executive function) [Beckmann et al., 2005; Damoiseaux
et al., 2006; Seeley et al., 2007; Smith et al., 2009]. Disrup-
tions of functional networks have been demonstrated in
both depressed and demented patients, especially for the
default mode network (DMN) [Hafkemeijer et al., 2012;
Sundermann et al., 2014; Wang et al., 2006]. Several studies
point to normalization of DMN connectivity in depression
after SSRI administration [McCabe and Mishor, 2011;
McCabe et al., 2011; Van de Ven et al., 2013; Van Wingen
et al., 2014]. Yet, there is also proof of more extensive
effects of SSRIs on brain connectivity [Klaassens et al.,
2015; Schaefer et al., 2014]. In AD patients, cholinergic
stimulation induces alterations in connectivity for DMN
regions [Goveas et al., 2011; Li et al., 2012; Sole-Padulles
et al., 2013], as well as networks involved in attention, con-
trol, and salience processing [Wang et al., 2014].
Characteristically, neuromodulators support the process-
ing of sensory information, coordination of motor output,
and higher order cognitive functioning [Foehring and
Lorenzon, 1999; Gu, 2002; Hasselmo, 1995]. In line with
the diverse and widespread patterns of effect of both
transmitters we investigated the direct influence of the
SSRI citalopram 30 mg and the AChEI galantamine 8 mg
on various brain networks. Both RS-fMRI and functional
(cognitive and neuroendocrine) responses were examined
in 12 healthy young volunteers in a repeated measures
fashion. Galantamine was hypothesized to mainly affect
connectivity with brain structures that are involved in
learning and memory mechanisms. Based on our previous
study with the SSRI sertraline 75 mg, we expected to see
widespread decreases in connectivity immediately after
citalopram administration in the absence of cognitive
change.
METHOD
Subjects
Twelve healthy young volunteers (mean age 22.16 2.7,
range 18–27; gender ratio 1:1, BMI 21–28 kg/m2) were
recruited to participate in the study. All subjects under-
went a thorough medical screening at the Centre for
Human Drug Research (CHDR) to investigate whether
they met the inclusion and exclusion criteria. They had a
normal history of physical and mental health and were
able to refrain from using nicotine and caffeine during
study days. Exclusion criteria included positive drug or
alcohol screen on study days, regular excessive consump-
tion of alcohol (>4 units/day), caffeine (>6 units/day) or
cigarettes (>5 cigarettes/day), use of concomitant medica-
tion 2 weeks prior to study participation, and involvement
in an investigational drug trial 3 months prior to adminis-
tration. The study was approved by the medical ethics
committee of the Leiden University Medical Center
(LUMC) and the scientific review board of the CHDR.
Written informed consent was obtained from each subject
prior to study participation.
Study Design
This was a single center, double blind, placebo-
controlled, crossover study with citalopram 30 mg and gal-
antamine 8 mg. Each subject received citalopram, galant-
amine and placebo on three different occasions with a
washout period in between of at least 7 days. Citalopram
has an average time point of maximum concentration
(Tmax) of 2–4 h, with a half-life (T1=2) of 36 h. For galant-
amine, Tmax5 1–2 h and T1=25 7–8 h. To correct for the dif-
ferent pharmacokinetic (PK) profiles of the compounds,
citalopram 20 mg was administered at T5 0 h, followed
by a second dose of 10 mg at T5 1 h (if the first dose was
tolerated and subjects did not become too nauseous).
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Galantamine was given as a single 8 mg dose at T5 2 h.
Blinding was maintained by concomitant administration of
double-dummy placebo’s at all three time points. All sub-
jects also received an unblinded dose of granisetron 2 mg
at T520.5 h, to prevent the most common drug-induced
adverse effects of nausea and vomiting.
Six RS-fMRI scans were acquired during study days,
two at baseline and four after administering citalopram,
galantamine or placebo (at T5 2.5, 3.5, 4.5, and 6 h post
dosing). Each scan was followed by performance of com-
puterized cognitive tasks (taken twice at baseline) on the
NeuroCartV
R
test battery, developed by the CHDR for
quantifying pharmacological effects on the CNS [Dumont
et al., 2005; Gijsman et al., 2002; Liem-Moolenaar et al.,
2011]. By including multiple measurements during the
Tmax interval, this repeated measures profile increases the
statistical power of the analysis and allows for identifica-
tion of time related effects, associated with changing
serum concentrations. Nine blood samples were taken dur-
ing the course of the day to define the PK profile of citalo-
pram, citalopram’s active metabolite desmethylcitalopram,
galantamine, and concentrations of cortisol and prolactin
[Jacobs et al., 2010b; Umegaki et al., 2009]. An overview of
the study design is provided in Figure 1.
Blood Sampling
Pharmacokinetics
Blood samples were collected in 4 mL EDTA plasma
tubes at baseline and 1, 2, 2.5, 3, 3.5, 4.5, and 6 h post dos-
ing, centrifuged (2,000g for 10 min) and stored at 2408C
until analysis with liquid chromatography-tandem mass
spectrometry (LC-MS/MS). PK parameters for citalopram,
galantamine and citalopram’s active metabolite desmethyl-
citalopram were calculated using a non-compartmental
analysis. Maximum plasma concentrations (Cmax) and time
of Cmax (Tmax) were obtained directly from the plasma
concentration data. The area under the plasma concentra-
tion versus time curve was calculated from time zero to
the time of the last quantifiable measured plasma concen-
tration, which is equal to the last blood sample of the
study day (AUC0-last). The calculated PK parameters were
not used for further analysis but investigated to validate
the choice of time points of measurements.
Neuroendocrine variables
Blood samples were also obtained to determine cortisol
and prolactin concentrations. Serum samples were taken
in a 3.5 mL gel tube at baseline (twice) and 1, 2, 2.5, 3.5,
4.5, and 6 h post dosing, centrifuged (2,000g for 10 min)
and stored at 2408C until analysis. Serum concentrations
were quantitatively determined with electrochemilumines-
cence immunoassay. Cortisol and prolactin concentrations
were subsequently used for statistical analysis using a
mixed effects model with treatment, time, visit and treat-
ment by time as fixed effects, subject, subject by treatment,
and subject by time as random effects and the average of
the period baseline (pre-dose) values as covariate (SAS for
Windows V9.4; SAS Institute, Inc., Cary, NC).
NeuroCart
VR
Test Battery
Each RS-fMRI scan was followed by functional CNS
measures outside the scanner using the computerized
NeuroCartV
R
test battery measuring alertness, mood, and
calmness [Visual Analogue Scales (VAS) Bond & Lader],
nausea (VAS Nausea), vigilance and visual motor perfor-
mance (Adaptive Tracking task), reaction time (Simple
Reaction Time task), attention, short-term memory, psy-
chomotor speed, task switching, and inhibition (Symbol
Digit Substitution Test and Stroop task), working memory
(N-back task) and memory imprinting and retrieval (Visu-
al Verbal Learning Test) [Bond and Lader, 1974; Borland
and Nicholson, 1984; Laeng et al., 2005; Lezak, 2004; Lim
et al., 2008; Norris, 1971; Rogers et al., 2004; Stroop, 1935;
Wechsler, 1981]. The Visual Verbal Learning Test was only
performed once during each day (at 3 and 4 h post
Figure 1.
Schematic overview of a study day. Each subject received citalo-
pram, galantamine, and placebo on three different days. At base-
line, two RS-fMRI scan were acquired, followed by the
NeuroCart
VR
CNS test battery. After drug administration, four
more RS-fMRI scans were acquired at time points T5 2.5, 3.5,
4.5, and 6 h post dosing, each time followed by the NeuroCart
VR
test battery. During the day, nine blood samples were taken to
measure the concentrations of citalopram, desmethylcitalopram,
galantamine, cortisol, and prolactin. On each study day there
were three moments of administration. The second administra-
tion only took place when subjects tolerated the first dose well
(did not vomit or feel too nauseous): Galantamine study day:
T5 0) placebo T5 1) placebo T5 2) galantamine 8 mg. Citalo-
pram study day: T5 0) citalopram 20 mg T5 1) citalopram
10 mg T5 2) placebo. Placebo study day: T5 0) placebo T5 1)
placebo T5 2) placebo.
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dosing) as the test itself consists of different trials (imprint-
ing and retrieval). Duration of each series of NeuroCartV
R
brain function tests was approximately 20 min. To mini-
mize learning effects, training for the NeuroCartV
R
tasks
occurred during the screening visit within 3 weeks prior
to the first study day.
Analysis
All within period repeatedly measured CNS endpoints
were analyzed using a mixed effects model with treatment,
time, visit and treatment by time as fixed effects, subject,
subject by treatment and subject by time as random effects
and the average of the period baseline (pre-dose) values as
covariate (SAS for Windows V9.4; SAS Institute, Inc., Cary,
NC). As data of the Simple Reaction Time task were not
normally distributed, these data were log-transformed
before analysis and back transformed after analysis. The
data of the Visual Verbal Learning test were analyzed
using a mixed effects model with treatment and visit as
fixed effects and subject as random effect. Treatment effects
were considered significant at P< 0.05 (uncorrected).
Imaging
Scanning was performed at the LUMC on a Philips 3.0
Tesla Achieva MRI scanner (Philips Medical System, Best,
The Netherlands) using a 32-channel head coil. During the
RS-fMRI scans, all subjects were asked to close their eyes
while staying awake. They were also instructed not to
move their head during the scan. Instructions were given
prior to each scan on all study days. T1-weighted anatomi-
cal images were acquired once per visit. To facilitate regis-
tration to the anatomical image, each RS-fMRI scan was
followed by a high-resolution T2*-weighted echo-planar
scan. Duration was approximately 8 min for the RS-fMRI
scan, 5 min for the anatomical scan and 30 sec for the
high-resolution scan. Heart rate signals were recorded dur-
ing each scan.
RS-fMRI data were obtained with T2*-weighted echo-pla-
nar imaging (EPI) with the following scan parameters: 220
whole brain volumes, repetition time (TR)5 2,180 ms; echo
time (TE)5 30 ms; flip angle5 858; field-of-view (FOV)5
220 3 220 3 130 mm; in-plane voxel resolution5 3.44 3
3.44 mm, slice thickness5 3.44 mm, including 10% interslice
gap. The next parameters were used to collect T1-weighted
anatomical images: TR5 9.1 ms; TE5 4.6 ms; flip angle5 88;
FOV5 224 3 177 3 168 mm; in-plane voxel resolution5
1.17 3 1.17 mm; slice thickness5 1.2 mm. Parameters of
high-resolution T2*-weighted EPI scans were set to:
TR5 2,200 ms; TE5 30 ms; flip angle5 808; FOV5 220 3
220 3 168 mm; in-plane voxel resolution5 1.96 3 1.96 mm;
slice thickness5 2.0 mm.
Analysis
All analyses were performed using the Functional Mag-
netic Resonance Imaging of the Brain (FMRIB) Software
Library (FSL, Oxford, United Kingdom) version 5.0.7 [Jen-
kinson et al., 2012; Smith et al., 2004; Woolrich et al., 2009].
Each individual functional EPI image was inspected,
brain-extracted and corrected for geometrical displace-
ments due to head movement with linear (affine) image
registration. Images were spatially smoothed with a 6 mm
full-width half-maximum Gaussian kernel and co-
registered with the brain extracted high resolution T2*-
weighted EPI scans (with 6 degrees of freedom) and T1
weighted images (using the Boundary-Based-Registration
method) [Greve and Fischl, 2009; Smith, 2002]. The T1-
weighted scans were non-linearly registered to the MNI
152 standard space (the Montreal Neurological Institute,
Montreal, QC, Canada) using FMRIB’s Nonlinear Image
Registration Tool. Registration parameters were estimated
on non-smoothed data to transform fMRI scans into stan-
dard space. Automatic Removal of Motion Artifacts based
on Independent Component Analysis (ICA-AROMA vs0.3-
beta) was used to detect and remove motion related arti-
facts. ICA decomposes the data into independent compo-
nents that are either noise related or pertain to functional
networks. ICA-AROMA attempts to identify noise compo-
nents by investigating its temporal and spatial properties
and removes these components from the data that are clas-
sified as motion related. Registration was thereafter
applied on the denoised functional data with registration
parameters as derived from non-smoothed data. As recom-
mended, high pass temporal filtering (with a high pass fil-
ter of 150 sec) was applied after denoising the fMRI data
with ICA-AROMA [Pruim et al., 2015a, 2015b].
RS-fMRI networks were thereafter extracted from each
individual denoised RS-fMRI dataset (12 subjects 3 3 days
3 6 scans5 216 datasets) applying a dual regression anal-
ysis [Beckmann et al., 2009; Filippini et al., 2009] based on
10 predefined standard network templates as used in our
previous research [Klaassens et al., 2015]. Confound
regressors of time series from white matter (measured
from the center of the corpus callosum) and cerebrospinal
fluid (measured from the center of lateral ventricles) were
included in this analysis to account for non-neuronal sig-
nal fluctuations [Birn, 2012]. The 10 standard templates
have previously been identified using a data-driven
approach [Smith et al., 2009] and comprise the following
networks: three visual networks (consisting of medial,
occipital pole, and lateral visual areas), DMN (medial pari-
etal (precuneus and posterior cingulate), bilateral inferi-
or–lateral–parietal and ventromedial frontal cortex),
cerebellar network, sensorimotor network (supplementary
motor area, sensorimotor cortex, and secondary somato-
sensory cortex), auditory network (superior temporal
gyrus, Heschl’s gyrus, and posterior insular), executive
control network (medial–frontal areas, including anterior
cingulate and paracingulate) and two frontoparietal
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networks (frontoparietal areas left and right). With the
dual regression method, spatial maps representing voxel-
to-network connectivity were estimated for each dataset
separately in two stages for use in within-group compari-
sons. First, the weighted network maps were simulta-
neously used in a spatial regression into each dataset. This
stage generated 12 time series per dataset that describe the
average temporal course of signal fluctuations of the 10
networks plus 2 confound regressors (cerebrospinal fluid
and white matter). Next, this combination of time series
was entered in a temporal regression into the same data-
set. This resulted in a spatial map per network per dataset
with regression coefficients referring to the weight of each
voxel being associated with the characteristic signal
change of a specific network. The higher the value of the
coefficient, the stronger the connectivity of this voxel with
a given network. These individual statistical maps were
subsequently used for higher level analysis.
To infer treatment effects of citalopram and galantamine
versus placebo across time as well as for each time
point separately we used non-parametric combination
(NPC) as provided by FSL’s Permutation Analysis for
Linear Models tool (PALM vs65-alpha) [Pesarin, 1990;
Winkler et al., 2016]. NPC is a multivariate method that
offers the possibility to combine data of separate, possibly
non-independent tests, such as our multiple time points,
and investigate the presence of joint effects across time
points, in a test that has fewer assumptions and is more
powerful than repeated-measurements analysis of variance
(ANOVA) or multivariate analysis of variance (MAN-
OVA). NPC testing was used in two phases to estimate for
each network whether connectivity was significantly dif-
ferent on drug relative to placebo days. First, tests were
performed for each time point using 5,000 synchronized
permutations. More specifically, to investigate changes in
voxelwise functional connectivity with each of the 10 func-
tional networks, four t-tests (drug vs. placebo) were per-
formed for all post-dose time points (T5 2.5, 3.5, 4.5, and
6 h), with average heart rate (beats/m) per RS-fMRI scan
as confound regressor [Khalili-Mahani et al., 2013]. The
average of the two baseline RS-fMRI scans was used as
covariate as well, by adding the coefficient spatial map as
a voxel-dependent regressor in the model. Second, tests
for the four time points were combined non-parametrically
via NPC using Fisher’s combining function [Fisher, 1932]
and the same set of synchronized permutations as men-
tioned above. Threshold-free cluster enhancement was
applied to the tests at each time point and after the combi-
nation, and the resulting voxelwise statistical maps were
corrected for the familywise error rate using the distribu-
tion of the maximum statistic [Smith and Nichols, 2009;
Winkler et al., 2014]. Voxels were considered significant at
P-values <0.05, corrected.
RESULTS
Pharmacokinetics
The time to reach maximum plasma concentrations
(Tmax) was highly variable for both citalopram and galant-
amine (see Fig. 2 for individual and median PK time pro-
files). Maximum plasma concentrations of citalopram were
reached between 1.93 and 6 h after the first dose (mean
Tmax: 2.996 1.18), and between 2.48 and 6.05 h (mean
Tmax: 4.926 1.33) for desmethylcitalopram. Cmax for citalo-
pram was between 20.4 and 42.4 ng/mL (mean Cmax:
35.86 6.34) and between 1.45 and 4.7 ng/mL (mean Cmax:
2.956 1.07) for desmethylcitalopram. AUC0-last was
Figure 2.
Median (bold line) and individual (thin lines) pharmacokinetic profiles for citalopram (left) and
galantamine (right) concentrations in nanograms per milliliter on semi-log scale. Gray bars illus-
trate moments of RS-fMRI acquisition post drug administration. Observations below limit of
quantification were dismissed.
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between 86.8 and 186 ng*h/mL (mean AUC0-last:
1466 25.2) for citalopram and between 5.43 and 18.6
ng*h/mL (mean AUC0-last: 11.76 4.78) for desmethylcitalo-
pram. Maximum plasma concentrations of galantamine
were reached between 0.5 and 4 h (mean Tmax:
2.676 1.11). Consequently, maximum concentrations were
reached between 2.5 and 6 h post zero point (mean Tmax:
4.676 1.11). Cmax for galantamine was between 25.6 and
61.4 ng/mL (mean Cmax: 40.76 10.4). AUC0-last was
between 49.1 and 152 ng*h/mL (mean AUC0-last:
95.16 27.7).
Cortisol and Prolactin
As shown in Figure 3a,b, concentrations of cortisol and
prolactin increased after citalopram, relative to placebo
(P< 0.01). There was no significant treatment effect of gal-
antamine on either neuroendocrine hormone concentration.
NeuroCart
VR
Test Battery
There were no significant treatment effects of citalopram
and galantamine on measures of cognitive performance.
Compared with placebo, galantamine increased the level
of nausea as measured with the VAS Nausea (P< 0.05).
Citalopram did not cause significant nausea (see Fig. 3c).
The effects of citalopram and galantamine on all cognitive
and subjective NeuroCartV
R
measures are summarized in
the Supporting Information.
Imaging
Citalopram: combined test
Combining the data of all post-dose time points, there
was a decrease in connectivity after administering citalo-
pram compared with placebo (Fig. 4a) between (1) the sen-
sorimotor network and the pre- and postcentral gyri,
supplementary motor area (SMA), precuneus, posterior
and anterior cingulate cortex (PCC/ACC), medial prefron-
tal cortex and cerebellum, and (2) the right frontoparietal
network and brain stem.
Citalopram: partial tests
Time specific effects of citalopram compared with place-
bo were explored by investigating changes in connectivity
for each partial test (each time point post dosing) that con-
tributed to the combined test (see Fig. 4b).
At T5 2.5 h after citalopram administration there were
no significant changes in connectivity.
At T5 3.5 h after citalopram administration there was a
decrease in connectivity between the right frontoparietal
network and the insula and Heschl’s gyrus.
At T5 4.5 h after citalopram administration there was a
decrease in connectivity between (1) the default mode net-
work and the precuneus, PCC, ACC, cerebellum, and left
Figure 3.
Least squares means percent change from baseline profiles of
cortisol and prolactin concentrations and nausea as measured
with the Visual Analogue Scales (with standard errors of the
mean as error bars).
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Figure 4.
Statistical maps of citalopram induced decreases in functional con-
nectivity. Networks are shown in green with decreases in connec-
tivity with the network in blue (at P< 0.05, corrected). Figure (a)
shows significant alterations in connectivity for all time points post
dosing combined (with coordinates in mm). Figure (b) shows signif-
icant alterations in connectivity for each time point separately.
Plots visualize the corresponding average time profiles of changes
in functional connectivity for citalopram (dotted line) and placebo
(continuous line) conditions (z-values with standard errors of the
mean as error bars). Coronal and axial slices are displayed in radio-
logical convention (left5 right). [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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temporal lobe, (2) the sensorimotor network and the pre-
and postcentral gyri, SMA, precuneus, PCC, ACC, medial
prefrontal cortex, planum temporale, and Heschl’s gyrus,
and (3) the right frontoparietal network and brain stem.
At T5 6 h after citalopram administration there was a
decrease in connectivity between the executive control net-
work and the middle and superior frontal gyrus.
Specifications of citalopram’s combined and partial
effects (sizes of significant regions and peak z-values) are
provided in Table I.
Galantamine: combined test
Combining the data of all post-dose time points, there
was an increase in connectivity after administering galant-
amine compared with placebo (Fig. 5a) between visual net-
work 2 (occipital pole) and the left and right hippocampus,
precuneus, thalamus, fusiform gyrus, precentral and superi-
or frontal gyrus, PCC, and cerebellum.
Galantamine: partial tests
Time specific effects of galantamine compared with pla-
cebo were explored by investigating changes in connectivi-
ty for each partial test (each time point post dosing) that
contributed to the combined test (see Fig. 5b).
At T5 2.5 h after galantamine administration there was
a decrease in connectivity between the default mode net-
work and precuneus, PCC, and calcarine cortex.
At T5 3.5 h after galantamine administration there was
(1) a decrease in connectivity between visual network 1
(medial visual areas) and the right hippocampus, PCC,
and ACC, and (2) an increase in connectivity between
visual network 2 (occipital pole) and the cerebellum.
At T5 4.5 h after galantamine administration there was
a decrease in connectivity between the left frontoparietal
network and the medial prefrontal cortex, precuneus,
PCC, and ACC.
At T5 6 h after galantamine administration there was
an increase in connectivity between (1) visual network 2
(occipital pole) and the hippocampus, brain stem, cerebel-
lum and fusiform cortex, and (2) the auditory network
and PCC, precuneus, and pre- and postcentral gyri.
Specifications of galantamine’s combined and partial
effects (sizes of significant regions and peak z-values) are
provided in Table II.
DISCUSSION
Single-dose SSRI and AChEI administration is usually not
sufficient to alter cognitive and behavioral states in depres-
sion or dementia [Burke et al., 2002; Dumont et al., 2005;
Lanctot et al., 2003; Repantis et al., 2010; Wagner et al.,
2004]. Pharmacological research and development is there-
fore often restricted to clinical trials that last for weeks or
even months. However, considering the acute elevations of
synaptic neurotransmitters, it is expected that changes will
already take place on a neural level, well before this results
in improved performance and clinical outcome. In our
study, both agents altered resting state functional connectiv-
ity within our time frame of measurements. The results of
our study replicate the finding that SSRIs can have an
immediate and widespread diminishing impact on interac-
tions of the healthy neural system [Klaassens et al., 2015;
Murphy et al., 2009; Schaefer et al., 2014]. In conjunction
with other SSRIs, citalopram had clear neuroendocrine
effects [Seifritz et al., 1996], but did not induce cognitive or
subjective changes as measured with the NeuroCartV
R
bat-
tery. Network effects of galantamine were more discrete
and variable over time. The relatively low dose and highly
variable PK properties of this drug in our study and an
unexpected delay in onset of galantamine’s Tmax, which
may in hindsight be related to a food interaction with lunch,
may have obscured the detection of more subtle fMRI
effects and time-related changes. Galantamine increased
nausea but did not alter cognitive or behavioral states.
Citalopram
In congruence with both task-related [Bruhl and Herwig,
2009; Murphy et al., 2009] and resting-state fMRI para-
digms with SSRIs [Klaassens et al., 2015; Schaefer et al.,
2014], citalopram rapidly lowered connectivity in several
cortical and subcortical regions. This is consistent with the
numerous afferent and efferent serotonergic fibers origi-
nating from the brain stem’s raphe nuclei [Baumgarten
and Grozdanovic, 1995]. Compared with our recent results
on the SSRI sertraline [Klaassens et al., 2015], there was
considerable overlap between the two SSRIs in direction
(decreased connectivity) and regions (ACC, PCC, precu-
neus, prefrontal cortex, midbrain, and motor cortex) of
effect, especially with respect to other pharmacological
compounds that usually show more restricted responses
[Khalili-Mahani et al., 2012; Klumpers et al., 2012; Niesters
et al., 2012]. Part of these findings is in line with RS-fMRI
studies in depressed patients who exhibit hyperconnectiv-
ity of cortical midline structures (ACC, PCC, precuneus,
and medial prefrontal regions) that are related to emotion
regulation and modulated by serotonin transmission [Kup-
fer et al., 2012; Sundermann et al., 2014]. It has been
hypothesized that this increase in connectivity in depres-
sion is representative of disruptions in self-consciousness
and rumination of negative thoughts [Hamilton et al.,
2011; Zhu et al., 2012]. An explanation of the overall inhib-
itory effect of acute SSRI exposure is the relative predomi-
nance of inhibitory 5-HT1 versus stimulatory 5-HT2
receptor subtypes [Peroutka and Snyder, 1979] that has
been demonstrated throughout the cortex [Amargos-Bosch
et al., 2004; Barnes and Sharp, 1999; Celada et al., 2013;
Lidow et al., 1989]. Most outstanding was the citalopram
induced decrease in connectivity with the sensorimotor
network, mainly due to alterations at T5 4.5 h. Citalopram
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TABLE I. Overview of significant decreases in functional connectivity after citalopram as estimated with threshold-
free cluster enhancement (P< 0.05, corrected)
Network NPC/T Region (Harvard–Oxford) z* x y z # voxels
Sensorimotor network NPC L/R/M ACC, PCC, precuneus,
SMA, post- and precen-
tral gyrus, medial, and
orbital frontal cortex
5.23 222 50 216 27,308
L/R/M Cerebellum 4.28 0 272 230 1,696
L/M Lateral occipital cortex,
inferior, and superior
division
4.20 214 292 20 585
R Cerebellum and temporal
occipital fusiform cortex
3.92 36 278 222 530
R/M Occipital pole and lingual
gyrus
3.28 8 296 26 92
L Superior frontal gyrus 3.25 218 32 28 91
Sensorimotor network T 5 4.5 L/R/M ACC, PCC, precuneus,
SMA, brain stem, post-
and precentral gyrus,
orbital frontal cortex
and cerebellum, lateral
occipital cortex, inferior,
and superior division
5.03 214 292 20 46,242
L Insular cortex, temporal,
and frontal opercular
cortex
4.91 238 16 24 498
M Thalamus 4.72 2 212 18 212
Frontoparietal network
right
NPC M Brain stem 4.42 2 226 216 55
Frontoparietal network
right
T 5 3.5 R Insular and central
opercular cortex
5.22 40 4 4 41
R Insular cortex and
Heschl’s gyrus
4.53 40 216 4 11
Frontoparietal network
right
T 5 4.5 L/R/M Brain stem and
cerebellum
4.43 8 244 218 1,655
L Frontal orbital cortex 3.72 226 8 214 45
L Parietal opercular cortex 3.78 232 244 28 34
Default mode network T 5 4.5 L/R Cerebellum 5.14 222 278 224 5,374
L/M Precuneus, PCC,
hippocampus, temporal,
and supramarginal
gyrus
4.56 236 258 28 2,407
L Lateral occipital cortex,
inferior, and superior
division
4.40 228 282 8 134
Executive control network T 5 6 R Precentral gyrus, inferior,
and middle frontal
gyrus
4.63 42 16 20 302
R Superior and middle
frontal gyrus
4.48 28 2 58 213
R Lateral occipital cortex,
inferior, and superior
division
3.91 56 270 24 187
R Inferior temporal gyrus 4.07 54 244 224 37
R Parietal operculum cortex 5.21 36 236 20 19
R Precentral gyrus 4.18 42 0 32 15
Abbreviations: L, left; R, right; M, midline; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; SMA, supplementary motor
area. Voxel dimension5 2 mm 3 2 mm 3 2 mm (voxel volume 0.008 mL). *5 standardized z-value of the uncorrected peak Fisher-
(NPC) or t-statistic (partial tests) within regions.
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also increased cortisol and prolactin levels, most noticeable
at one time point as well (T5 2.5 h for cortisol and
T5 3.5 h for prolactin). Although this took place before
appearance of the largest alterations in connectivity, it pos-
tulates an apex in the pharmacodynamic effect of citalo-
pram. Equal SSRI effects for the sensorimotor network
(decreased connectivity with the sensorimotor region, sup-
plementary motor area, precuneus, and cingulate cortex)
have been found earlier [Klaassens et al., 2015]. The prima-
ry motor and somatosensory cortex are both characterized
by a high 5-HT axon density [Wilson and Molliver, 1991]
and serotonin is recognized to be important for motor
behavior in animals and humans [Geyer, 1996; Hindmarch,
1995]. This is demonstrated by enhanced motor area activi-
ty during improved motor performance after SSRI admin-
istration [Loubinoux et al., 2002a,b]. The precuneus and
cingulate cortex are presumed to support voluntary and
complex motor control [Cavanna and Trimble, 2006; Shima
and Tanji, 1998] and seem to play a central role in SSRI
enhancement [Klaassens et al., 2015]. While the effect was
more focal, connectivity between the midbrain and right
fronto-parietal network was decreased as well. This
matches observations that acute blockade of serotonin
reuptake activates 5-HT1A autoreceptors in the midbrain’s
median and dorsal raphe nuclei [Briley and Moret, 1993;
Daubert and Condron, 2010; Jacobs and Azmitia, 1992], in
turn leading to reduced 5-HT release in particularly the
forebrain [Adell et al., 2002; Bel and Artigas, 1992].
Nevertheless, comparing effects of citalopram and ser-
traline, we did not find alterations in relation to exact
identical functional networks. No differences have been
found on the antidepressant efficacy of both SSRIs [Ekse-
lius et al., 1997; Stahl, 2000], although sertraline induces
more gastrointestinal side effects than citalopram [Ekselius
et al., 1997; Stahl, 2000]. This corresponds to our finding
that sertraline significantly increased the level of nausea,
whereas this did not occur in our current study group.
Citalopram is also known as the most selective SSRI; ser-
traline has more affinity for dopamine, noradrenaline, and
r-receptors than citalopram [Carrasco and Sandner, 2005],
which in turn modulate N-methyl-D-aspartate and gluta-
mate receptors as well [Urani et al., 2002]. Citalopram, on
the other hand, has a high affinity on histamine H1 recep-
tors [Carrasco and Sandner, 2005]. It is possible that these
properties may account for differences in network changes
between the two SSRIs [Cole et al., 2013; Villemagne et al.,
1991]. However, it is yet to be established what the value
is of specific network versus region effects in connectivity
analyses. Considering the resemblance in direction and
location of effect we presume that sertraline and citalo-
pram induce quite comparable connectivity alterations.
Galantamine
The cholinergic system is mostly related to aging and
aging related diseases, as cholinergic malfunction,
especially in the hippocampus, cortex, the entorhinal area,
the ventral striatum, and the basal forebrain, plays a key
role in associated functional degeneration [Kasa et al., 1997;
Schliebs and Arendt, 2011]. Combining fMRI data of all
time points, we found an increase in connectivity with the
visual network which was mostly associated with effects on
T5 6 h. The medial and lateral cholinergic pathways, origi-
nating from Meynert’s basal nucleus, supply a large portion
of the brain and merge in the posterior occipital lobe [Selden
et al., 1998]. In dementia and schizophrenia, it is hypothe-
sized that cholinergic dysregulation is responsible for psy-
chotic manifestations and AChEIs have been successfully
used for treatment of visual hallucinations [Bentley et al.,
2008; Sarter and Bruno, 1998]. ACh release in the primary
visual cortex is increased during visual stimulation pointing
to ACh as influencing visual processing and learning mech-
anisms [Dotigny et al., 2008; Kang et al., 2014]. It has been
proposed that cholinergic enhancement facilitates bottom-
up visual attention and perception by increasing activity in
the extrastriate cortex [Bentley et al., 2003, 2004]. More
importantly, galantamine altered connectivity with areas
that are highly relevant in learning and memory: the left
and right hippocampus and thalamus. Changes in choliner-
gic markers such as choline acetyltransferase, acetylcholin-
esterase, and muscarinic and nicotinic acetylcholine
receptor availability in hippocampal regions is typical for
AD and normal aging [Schliebs and Arendt, 2011]. In
patients with AD, hippocampal volume loss appears to
slow down during treatment with donezepil [Hashimoto
et al., 2005] and cholinergic enhancement even improved
visual and verbal memory episodic memory and long-term
visual episodic recall in healthy young subjects, memory
domains that are specifically related to hippocampal func-
tioning [Gron et al., 2005]. Cholinergic treatment aided the
processing of novel faces in AD patients, which was accom-
panied by normalization in the fusiform gyrus [Kircher
et al., 2005; Rombouts et al., 2002], where we found connec-
tivity changes as well. In addition, acute exposure to cholin-
ergic stimulation increased activation in occipital and
hippocampal regions of patients with AD and mild cogni-
tive impairment (MCI) during a visual memory task [Goe-
koop et al., 2004, 2006]. The thalamus, considered to be a
gate for sensory information, contains various nuclei that
receive excitatory cholinergic input [McCance and Phillis,
1968], including the lateral geniculate nucleus that has feed-
back connections with the primary visual cortex [Phillis
et al., 1967; Sillito et al., 2006]. Results for this network are
compatible with previous studies [Furey et al., 2000; Mur-
phy and Sillito, 1991], indicating that cholinergic enhance-
ment benefits memory performance and visual stimulation
orientation by selective perceptual processing.
Repeated Measures
Collecting multiple scans per day increases the power of
the statistical test and decreases individual variability,
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Figure 5.
Statistical maps of galantamine induced increases and decreases
in functional connectivity. Networks are shown in green with
increases in connectivity with the network in red and decreases
in connectivity in blue (at P< 0.05, corrected). Figure (a) shows
significant alterations in connectivity for all time points post dos-
ing combined (with coordinates in mm). Figure (b) shows signifi-
cant alterations in connectivity for each time point separately.
Plots visualize the corresponding average time profiles of
changes in functional connectivity for galantamine (dotted line)
and placebo (continuous line) conditions (z-values with standard
errors of the mean as error bars). Coronal and axial slices are
displayed in radiological convention (left5 right). [Color figure
can be viewed in the online issue, which is available at wileyonli-
nelibrary.com.]
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which reduces the need for large sample sizes. The
observed variation in connectivity on placebo days empha-
sizes the importance of a placebo-controlled design with
repeated measures, providing insight into potential diur-
nal fluctuations. Furthermore, it offers possibilities to
investigate effects on different time points and relate these
effects to other pharmacodynamic and PK profiles. NPC
groups the data of all time points to test one joint null
hypothesis without the necessity to explicitly model their
dependence [Pesarin, 1990; Winkler et al., 2016], ending
up with effects among them that are statistically most
robust. In addition, univariate partial tests allow for infer-
ence per time point. For citalopram, it might have been
sufficient to acquire scans at one time point (T5 4.5 h).
However, it is largely impossible to predict beforehand at
which specific moment we can expect the most stable and
“real” drug effect, since the peak effect does not appear to
coincide directly with the observed Tmax in plasma and
neuroendocrine responses. Effects at other time points
may not reach significance but still contribute to the net
result. The combined outcome therefore tends to be more
reliable and powerful in defining pharmacological effects
that are variable over time, as it will grasp the strongest
effects without the risk of missing out on important infor-
mation [Fisher, 1932]. This does not imply that the partial
(time specific) effects are meaningless. A decrease in con-
nectivity at T5 4.5 h between the default mode network
and precuneus, PCC and ACC is in line with earlier
results [Klaassens et al., 2015; McCabe and Mishor, 2011;
McCabe et al., 2011; Van de Ven et al., 2013; Van Wingen
et al., 2014] and in agreement with opposite features in
depression, which is characterized by increased connectivi-
ty of DMN components [Sundermann et al., 2014]. Espe-
cially the posterior part of the DMN, where citalopram
effects were most prevalent, has been implicated in SSRI
efficacy in depression [Greicius et al., 2007; Li et al., 2013].
Furthermore, consistent with an increased cerebellar-DMN
connectivity in depression [Sundermann et al., 2014], cita-
lopram reduced connectivity between the DMN and cere-
bellum. The cerebellum is primarily known for its service
in motor control, illustrating our findings for the sensori-
motor network, but influences mood regulation as well
[Schmahmann, 2004; Schmahmann and Sherman, 1998].
In contrast to citalopram, the effects of galantamine
were more focal, less related to a specific network or point
in time and less uniform with regard to direction of effect.
This heterogeneity in effect possibly reflects the large
kinetic variability in this study. Although the variation in
timing of Tmax did not clearly differ between citalopram
and galantamine, the variance of galantamine’s Cmax
(ranging from 25.6 to 61.4 ng/mL) was high compared
with citalopram and desmethylcitalopram. Since the com-
bined effect mainly depended on the last time point it is
possible that the impact of galantamine does not follow a
time course that equals the PK profile or that effects might
have become larger and more stable later in time. This is
congruent with the unanticipated delay in onset of galant-
amine’s Tmax in our study group, resulting in a less pow-
erful aggregation of data, in which especially the value of
measurements at T5 2.5 is questionable. Although galant-
amine is known for a Tmax of 1–2 h after dosing, the mean
Tmax in our sample was 2.67 h (4.67 h after zero point),
whereas citalopram, known for a Tmax between 2 and 4 h,
did reach its maximum concentration at 2.99 h post dos-
ing. Furthermore, the relatively low dose and variable
kinetic time profile of galantamine might have contributed
to the absence of a larger response on functional connec-
tivity and neuroendocrine parameters. A larger sample
size, a higher dose of galantamine (16–32 mg), and earlier
drug administration might have reduced this variability in
response. The outcomes of our partial tests reveal addi-
tional information beyond the combined approach as well.
There is a tendency toward diminished DMN activity in
normal aging, MCI and dementia, pointing to reduced
integrity of structures that are vulnerable to atrophy, beta
amyloid deposition and reduced glucose metabolism [Haf-
kemeijer et al., 2012]. Studies that are performed on the
resting state fMRI response to cholinergic interventions are
restricted to AD patients and mainly indicate an increase
in connectivity with DMN areas [Goveas et al., 2011; Li
et al., 2012; Sole-Padulles et al., 2013]. In another study, no
effect on the DMN was found in both APOE e4 carriers
and non-carriers [Wang et al., 2014]. Acute exposure to
cholinergic stimulation decreased DMN connectivity with
the precuneus and occipital cortex in our study group at
T5 2.5 h. This direction of effect might be the consequence
of investigating cholinergic responses in healthy young
adults instead of subjects with impaired cholinergic sys-
tems. It is possible that when neural cholinergic processes
are still intact, ceiling effects may prevent further activa-
tion and excessive stimulation may actually impair opti-
mal connectivity. Moreover, these studies all used AChEI
treatment for several weeks, instead of our single-dose
administration. More research is needed to unravel differ-
ential cholinergic responses among specific populations
and treatment designs.
Limitations
Agents that enhance the cholinergic and serotonergic
system commonly elicit gastrointestinal adverse events,
which is attributable to their peripheral influences [Gauth-
ier, 2001; Trindade et al., 1998]. In order to prevent these
adverse effects, we administered granisetron on both
drug- and placebo study days before study drug adminis-
tration. RS-fMRI effects of selective 5-HT3 receptor antago-
nists as granisetron are lacking, but need to be taken into
consideration when interpreting the results [Jacobs and
Azmitia, 1992]. However, intolerability to our intensive
study procedures would have been undesirable [Jacobs
et al., 2010a] and vomiting might have altered brain con-
nectivity as well. To reduce nausea, we also decided to
r Klaassens et al. r
r 12 r
TABLE II. Overview of significant decreases (#) and increases (") in functional connectivity after galantamine as esti-
mated with threshold-free cluster enhancement (P<0.05, corrected)
Network NPC/T Region (Harvard–Oxford) z* x y z # voxels
Visual network 2 (") NPC L/R/M Hippocampus, thalamus,
precuneus, PCC, lateral
occipital cortex, brain stem,
fusiform gyrus, superior
frontal gyrus, precentral gyrus,
and cerebellum
4.84 2 262 226 10,765
L/M Cerebellum and brain stem 4.21 8 248 244 1,249
M Precuneus and PCC 3.10 28 240 54 147
R Frontal orbital cortex 4.09 34 32 0 31
R Inferior frontal gyrus 3.56 48 14 14 25
R Frontal operculum cortex 3.40 50 10 22 16
Default mode
network (#)
T 5 2.5 R/M Precuneus, PCC, and calcarine
cortex
4.36 10 258 26 210
R Lateral occipital cortex, superior
division
4.34 40 272 28 74
M Lingual gyrus 3.70 4 254 2 15
Visual network 1 (#) T 5 3.5 M ACC and paracingulate gyrus 4.41 8 22 18 246
R Precuneus and PCC 3.64 14 256 16 210
R Superior temporal gyrus,
Heschl’s gyrus, and planum
polare
4.06 48 226 0 105
R/M ACC, paracingulate gyrus,
superior, and inferior frontal
gyrus
3.65 14 8 38 93
L Lingual gyrus, parahippocampal
gyrus
3.46 218 246 212 91
R Pallidum, amygala, and putamen 4.54 18 2 28 76
Visual network 2 (") T 5 3.5 R Cerebellum 4.79 24 266 236 14
Visual network 2 (") T 5 6 L/R/M Hippocampus, parahippocampal
gyrus, cerebellum, brain stem,
temporal occipitalfusiform cortex
and inferior temporal gyrus
5.01 8 248 244 4,876
R Lateral occipital cortex, superior
division
4.24 28 262 52 677
R Precentral gyrus, superior, and
middle frontal gyrus
3.85 32 28 38 470
R PCC, precuneus, and precentral
gyrus
4.32 14 224 44 372
L Precuneus and lateral occipital
cortex, superior division
3.66 218 268 52 152
R Lateral occipital cortex, superior
division
3.62 42 276 30 146
Frontoparietal
network left (#)
T 5 4.5 L/R/M Frontal medial cortex and ACC 5.25 22 52 22 630
R Precuneus and PCC 4.12 16 250 12 110
R Parahippocampal gyrus,
posterior division
4.53 12 230 216 44
R Temporal occipital fusiform
cortex and lingual gyrus
3.44 36 242 210 14
Auditory network (") T 5 6 L/M PCC, precuneus, and precentral
gyrus
4.83 24 232 48 188
L Postcentral gyrus 4.65 246 228 50 23
Abbreviations: L, left; R, right; M, midline; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex. Voxel dimension5 2 mm 3
2 mm 3 2 mm (voxel volume 0.008 mL). *5 standardized z-value of the uncorrected peak Fisher- (NPC) or t-statistic (partial tests) with-
in regions.
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administer citalopram in two doses, and to skip the second
dose in case of tolerability issues. For citalopram, our mea-
sures were adequate, and all subjects received both doses
without significant nausea. For the same reasons, a rela-
tively low dose of galantamine was chosen. However,
increased nausea was present after administering galant-
amine compared with placebo, primarily at the end of the
day, which may also have influenced some of the
observed network effects but justifies our decision to limit
the dose of galantamine. This also emphasizes the mis-
match of our repeated measurements and galantamine’s
absorption rate. Despite our attempt to equalize the PK
responses of citalopram and galantamine during the
course of the day, both drugs did not reach their maxi-
mum concentration at the same time point, which hampers
comparability. Currently, no accepted methods are avail-
able to include individual drug concentrations in the net-
work analysis. Further, fMRI effects, especially in
pharmacological research, are potentially the result of
vasodilation, and hence to changes in neurovascular cou-
pling instead of true neural activity [Rack-Gomer and Liu,
2012; Wong et al., 2012]. Although SSRIs do not typically
alter the hemodynamic response [Feczko et al., 2012],
AChEIs could increase vessel tone by contraction of the
smooth muscles of blood vessels [Rosengarten et al., 2009;
Stephenson and Kolka, 1990]. Yet, there was no significant
treatment effect of either drug on heart rate frequency,
which minimizes the probability of cardiac artifacts.
Besides, vessel dilation would more likely alter connec-
tions throughout the entire brain instead of inducing the
network-specific effects that we observed. Lastly, the
observed changes in regional connectivity might partly be
the result of drug-induced reductions of neuronal activity
in the BOLD signal leading to a reduced signal to noise
ratio. Future studies with appropriate protocols are needed
to specify these processes more accurately.
Summary
This study provides further support for RS-fMRI as a
sensitive method for investigating instant neural processes
after pharmacological challenges. The results on the SSRI
citalopram and AChEI galantamine identify their neuro-
modulating role in cognitive and sensory systems. Citalo-
pram altered connectivity with networks and regions that
are mostly implied in sensorimotor functioning and self-
reference, whereas the results of galantamine show acetyl-
choline’s relation to visual processing and learning mecha-
nisms. Our findings also encourage the use of repeated
measurements after single-dose administration, leading to
a more powerful and reliable picture of pharmacological
effects. Results may have been partially obscured by the
variability of individual PK characteristics, which was
larger than expected. A future challenge therefore is to
develop appropriate statistical models (PK/PD-modeling)
to investigate concentration-dependent modulation of rest-
ing state functional connectivity.
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